Is the Tumour Microenvironment a Critical Prognostic Factor in Early-stage Colorectal Cancer?

Overview

Journal Ann Oncol

Publisher Elsevier

Specialty Oncology

Date 2019 Sep 11

PMID 31504141

Citations 2

Authors

G Nyamundanda

E Fontana

A Sadanandam

Affiliations

Soon will be listed here.

Citing Articles

Role of Epithelial to Mesenchymal Transition in Colorectal Cancer.

Lu J, Kornmann M, Traub B Int J Mol Sci. 2023; 24(19).

PMID: 37834263 PMC: 10573312. DOI: 10.3390/ijms241914815.

miR-18a-5p and ATM Expression in Esophageal Squamous Cell Carcinoma and Their Correlations with Clinicopathological Features.

Qi J, Fan W Comput Math Methods Med. 2022; 2022:5260608.

PMID: 36267307 PMC: 9578886. DOI: 10.1155/2022/5260608.

References

Schlicker A, Beran G, Chresta C, McWalter G, Pritchard A, Weston S . Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. BMC Med Genomics. 2013; 5:66. PMC: 3543849. DOI: 10.1186/1755-8794-5-66. View

Pages F, Mlecnik B, Marliot F, Bindea G, Ou F, Bifulco C . International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018; 391(10135):2128-2139. DOI: 10.1016/S0140-6736(18)30789-X. View

Lenz H, Ou F, Venook A, Hochster H, Niedzwiecki D, Goldberg R . Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance). J Clin Oncol. 2019; 37(22):1876-1885. PMC: 6675593. DOI: 10.1200/JCO.18.02258. View

Calon A, Lonardo E, Berenguer-Llergo A, Espinet E, Hernando-Momblona X, Iglesias M . Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet. 2015; 47(4):320-9. DOI: 10.1038/ng.3225. View

Roepman P, Schlicker A, Tabernero J, Majewski I, Tian S, Moreno V . Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer. 2013; 134(3):552-62. PMC: 4234005. DOI: 10.1002/ijc.28387. View

de Sousa E Melo F, Wang X, Jansen M, Fessler E, Trinh A, de Rooij L . Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med. 2013; 19(5):614-8. DOI: 10.1038/nm.3174. View

Song N, Pogue-Geile K, Gavin P, Yothers G, Kim S, Johnson N . Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial. JAMA Oncol. 2016; 2(9):1162-9. PMC: 5065181. DOI: 10.1001/jamaoncol.2016.2314. View

Petrelli F, Tomasello G, Borgonovo K, Ghidini M, Turati L, Dallera P . Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2016; 3(2):211-219. DOI: 10.1001/jamaoncol.2016.4227. View

Fontana E, Eason K, Cervantes A, Salazar R, Sadanandam A . Context matters-consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials. Ann Oncol. 2019; 30(4):520-527. PMC: 6503627. DOI: 10.1093/annonc/mdz052. View

10.

Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J . Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer. 2017; 17(2):79-92. DOI: 10.1038/nrc.2016.126. View

11.

Dienstmann R, Mason M, Sinicrope F, Phipps A, Tejpar S, Nesbakken A . Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study. Ann Oncol. 2017; 28(5):1023-1031. PMC: 5406760. DOI: 10.1093/annonc/mdx052. View

12.

Marisa L, De Reynies A, Duval A, Selves J, Gaub M, Vescovo L . Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med. 2013; 10(5):e1001453. PMC: 3660251. DOI: 10.1371/journal.pmed.1001453. View

13.

Guinney J, Dienstmann R, Wang X, De Reynies A, Schlicker A, Soneson C . The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21(11):1350-6. PMC: 4636487. DOI: 10.1038/nm.3967. View

14.

Labianca R, Nordlinger B, Beretta G, Mosconi S, Mandala M, Cervantes A . Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24 Suppl 6:vi64-72. DOI: 10.1093/annonc/mdt354. View

15.

Dienstmann R, Villacampa G, Sveen A, Mason M, Niedzwiecki D, Nesbakken A . Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer. Ann Oncol. 2019; 30(10):1622-1629. PMC: 6857614. DOI: 10.1093/annonc/mdz287. View

16.

Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T . Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011; 29(6):610-8. DOI: 10.1200/JCO.2010.30.5425. View

17.

Budinska E, Popovici V, Tejpar S, dArio G, Lapique N, Sikora K . Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J Pathol. 2013; 231(1):63-76. PMC: 3840702. DOI: 10.1002/path.4212. View

18.

Kennecke H, Yin Y, Davies J, Speers C, Cheung W, Lee-Ying R . Prognostic effect of sidedness in early stage versus advanced colon cancer. Health Sci Rep. 2019; 1(8):e54. PMC: 6266477. DOI: 10.1002/hsr2.54. View

19.

Sadanandam A, Lyssiotis C, Homicsko K, Collisson E, Gibb W, Wullschleger S . A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med. 2013; 19(5):619-25. PMC: 3774607. DOI: 10.1038/nm.3175. View